About Atossa Genetics
Atossa Genetics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.
Atossa Genetics’ Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density
This is what we are looking for, go long with this CV company. Find a good entry point and squat!! If FDA approved this will go back where it cam from $$$
The rumor mill continues to spin in ATOS prior to a presentation scheduled for April the 25th, the spike in volume hopefully preempts a positive move. Keep it on the watchlist.
Atossa Genetics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, yesterday FDA Aprroved Oral Endoxifen for breast cancer patient.
Endoxifen is an active metabolite of tamoxifen, which is an FDA-approved drug to prevent new as well as recurrent disease in breast...
look for a long after breaking of trend and pull back to the level it broke up, if this level holds should be good indication of going up to the next levels.
Don't have time to lay out the details. Recent squeeze, warrants didnt get exercised either. Chance that this next squeeze will follow through with an offering
SHORT TERM TRADE
Yesturday marked a possible buy signal. The price action is making newer lows, while the MACD is making higher highs, this marks a bullish divergence. Tomorrow should be the confirmation of this signal, if and only if this it closes higher than todays close.
The pennant pattern is starting to tighten, look for ATOS to test top trendline. If it breaks, could trend upwards to test first price target. The stop loss is set in the case it breaks the pattern.
Atossa Genetics Inc. is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ (DCIS) and breast cancer. Its second pharmaceutical program under development is Afimoxifene Topical Gel (AfTG) for the treatment and prevention of hyperplasia of the breast. It is also engaged in the process of evaluating other therapeutic candidates to treat other breast conditions, including breast cancer. Its medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator. These devices are intended for the collection of nipple aspirate fluid (NAF) for cytological testing at a laboratory.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
ATOS
